Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
More like a huge decrease get ready to buy more as you call them cheap AMBS shares at .05 cents
Not only that I thought ESS would be worth more. Now the CEO stated the other day that ESS is worth $100 mil on the market. All the trouble to develop it the next 3 to 4 years and then $100 mil if they are lucky? And that's if it passes all trials and is approved by the FDA.
AMBS is toast with dilution heading lower, for another reverse split.
I'm surprised you gave AMBS 0.05 cents that is generous. I was thinking more like .02 or .03 cents soon.
I could have told you that back in 2014/2015. When Gerald promised Lympro Revenue and never delivered. He talked about CLIA certification and that Lympro would make money from doctors and big pharma. He peddled all that noise to suck investors in, all lies.
I told people every time this company releases pump news so they can further dilute the float. Look at today 3.8 mil shares guaranteed a lot of it was dilution. Gerald left all you shareholders out to dry. He is making a killing yearly salary doing nothing to create shareholder value. Gotta love em....
Lmypro was to be having revenue by 2015, here we are in 2016 and we have not heard a peep about Lympro CLIA certification or revenue. Also what about MANF for retinitis pigmentosa? NuroPro? MS precise? etc. ??? what happened to all those?
More convertible preferred series H. Conversions posted 20 hours ago
http://finance.yahoo.com/news/amarantus-announces-3m-capital-infusion-233700605.html
That means more dilution ahead like another poster stated next stop .12 cents
Oh also I forgot about warrants as well.
I don't think he really cares! Would you care? if you were making $634,000 dollars per year doing nothing?
Nice nickname it may actually stick... but yah no Lympro revenue still as that was peddled for a long time, and now they are peddling ESS. SCAMARANTUS is correct
So that was posted Nov 19, 2015 where the CEO said 0 to 100 real quick, yet here AMBS sits at .20 cents per share now .... haha
Still that's not a lot of money for a big pharma not to acquire. For a wound product that could potentially make billions of dollars why wasn't big pharma tripping over it to acquire it? doesn't make sense sorry
There is no doubt that investors are disgruntled which is why they are voicing their opinion. They are painting the truth and the truth is that nothing is rosy here. ESS is a dermatological product that has been passed on by other companies. If it was so great why did no other big pharma or other company pony up big money for it. It was bought on the cheap so Gerald could keep his paycheck and keep his dilution machine running.
They bought it for a measly $2.5 million. If it was so great it would have been worth much more.
"As required under the Agreement, Amarantus made the final payments due to Regenicin in the amount of $2.3 Million, along with a payment of $200,000 to Regenicin's senior secured creditor. In addition, Regenicin with Amarantus and Lonza Group, Ltd and its related entities, have signed a Settlement Agreement in the company's lawsuit with Lonza Group, Ltd and its related entities. Regenicin has filed a joint dismissal of all claims, known or unknown, in the Lonza matter."
That's the one about Elto hold thank you for finding it
I would have to try to dig to find it but I believe it was in a chairman's blog of the CEO's. They said they had to put a hold temporary on it because of money. will have to try to find the link for u
it was put on hold because of money issues. ODD can be applied at anytime of the clinical stage process. AMBS didn't have to wait on ODD status to begin the phase 2 trial for Elto.
But ESS is dermatology. What does dermatology have to do with Parkinson's disease and Alzheimer's? That's why a lot of the board of directors left because they didn't like the direction of the company. Forget ESS the company should have stuck with advancing Eltoprazine. Instead they put that on hold for awhile so they could advance ESS dumb move. The company is going nowhere with Gerald as CEO.
Not to mention Gerald is taking a $640k salary while doing all of these horrendous things.
He is because him and the board of directors always said they would uplist to NASDAQ from strength. Why didn't they just stay on the OTC until they had good news to release and or uplist? I will tell you why Gerald wanted to reverse split so that he could do more toxic financing. He could care less about the company as long as he gets that $600,000 dollar yearly salary.
What he needs to do is cut his salary down to say $80,000 dollars and use the rest of the money to fund the company. But he could care less he is being paid to do nothing but destroy shareholder value.
More SEC filings.
Stock options granted to 7 insiders in after-hours tonight.
The CEO has option to buy 133,000 shares after the first vested year. It will be quarterly the first time around then monthly thereafter for 3 to 4 years. Good stuff. Keep the good news coming RXII
New SEC filing after hours today Broadfin capital just increased their stake of RXII to 9.99% ownership.
http://www.snl.com/Cache/c32919898.html
Today's PR was just that, to help toxic lenders dump shares on the market. Look at the volume today 1.8 mil shares.
he is trying to get something signed, we will see if he is working on getting it done.
As for the delisting it won't happen. Two things will occur either the CEO gets a partnership with upfront payment or the company will have to reverse split to stay listed on the NASDAQ.
Plus the OTC is the worst for shorting you have NITE and CANT who are evil and toxic they short about 80% to 90% of stocks on the OTC.
All funds are bringing their shares down to 4.99% just below 5%. is it so they can exercise their warrants to buy them and add more money for the company? or is something else going on behind the scenes? Thus far 3 big funds have brought their shares at exactly 4.99% not a penny lower? Huge coincidence?
I don't know why people are so quick to judge JP on his stance for Amarantus. What he says is the truth. All the investors want to see is the CEO being honest -- which he hasn't delivered on anything promised -- and to find financing that is not toxic.
These 2 items have killed the share price. If both things magically turn around then the company might have a chance but I don't see that happening unfortunately with Gerald at the helm of the CEO role.
Yah short interest is down, but we need a partnership before May for sure.
This company will need to release some stellar results or a huge partnership with upfront money otherwise I don't see how a reverse split will be avoided. The CEO has the tech, the platform, the pipeline. if he really is a good CEO he needs to get a deal done before the reverse split.
I donno, maybe to Gerald that's Strength.........
Before anyone blasts me I was just being sarcastic ^^
More than likely this is headed back down to .08 cents per share before the reverse split. Then management can do another reverse split and promise NASDAQ listing once again dangling the carrot for new investors.
I told people in the morning that this deal was bad and that it would print new 52-week low. I was right on target on my post from the morning. Shareholders aren't happy at all, they were expecting what was promised. Spin out on Diagnostics company as separate company and then receive free shares of .. said company.
Instead GC merged with another no-name diagnostics company that lost $3 million last year, and trades like crap on the OTC as well.
if you are greek heed my warning, I'm greek too.
Na Mi Ise malakas ^^
AMBS will head lower
DX is worth nothing. It doesn't even have CLIA yet, and it generates 0 revenue for the company as of now. I don't know what the heck you are talking about? Look at the share price and volume, investors are unhappy with this deal they are bailing out. New 52 week low for AMBS coming
What is up with this merger? I thought Gerald said he was going to spin out the diagnostic division into a separate entity? Well looks like shareholders got borked again. Glad I don't any shares of this company, but it is funny to watch this disaster of a CEO operate.
Sell? No way, Gerald will not sell at all, he loses his chance to collect a $600,000 yearly paycheck. Plus his father is on the BOD so he isn't going to fire his own son. Pretty much shareholders here are screwed.
Hopefully Rxi Pharmaceuticals will have some news on Monday when they present. If not it would be nice to at least get an update on potential catalysts for 2016, and other new info. We shall See good luck to all long term shareholders.
That's probably when the final transaction was completed but not when it was initiated. Look below:
On November 17, 2014, Amarantus Bioscience Holdings, Inc. (AMBS) announced that it has entered into an exclusive option agreement with Lonza Walkersville, Inc. to acquire Cutanogen Corporation. Both Lonza Walkersville and Cutanogen Corp. are subsidiaries of Lonza Group Ltd. Acquiring Cutanogen gives Amarantus rights to develop Engineered Skin Substitute (“ESS”), an autologous skin replacement product for the treatment of Stage 3 and Stage 4 intractable severe burns. Below we provide a brief background on the financial terms of the deal, the history and clinical use of ESS, how it fits into the Amarantus portfolio, and conclude with some thoughts on the deal and the Amarantus story.
http://finance.yahoo.com/news/ambs-astute-deal-brings-another-193000455.html
Clearly it was first started to be acquired in November 17, 2014. JP was right
They have nothing. They are not working on the pipeline. They now chose to boost the ESS candidate but that's a dermatology product -- skin substitute -- nothing to do with Alzheimer's or Parkinson's disease.
Gerald just continues to add new stuff to the pipeline to keep collecting a paycheck. I don't like the way he has developed this company.
And remember when they briefly put the Eltoprazine trial on hold for a long time? Just tell him to develop the pipeline and forget about ESS nonsense. Glad I don't hold any shares in this company, I just feel bad for the shareholders who have been fleeced for years.
Rxi Pharmaceuticals Has updated their website now! Looks really good, and things coming along. Looks like possible partnership coming soon as well.
http://www.rxipharma.com/
There is no doubt that this will move. Two phase 2 trials one in hypertrophoic scars now another in warts with Samcyprone. also phase 1/2 trial in retinal scarring of macular degeneration. This will take off one day and when it does it will be big.